Cheng Zhen-Ying, Wang Xu-Ping, Schmid Katrina L, Han Yu-Fei, Han Xu-Guang, Tang Hong-Wei, Tang Xin
Clinical College of Ophthalmology, Tianjin Medical University, Tianjin Eye Hospital, 4 Gansu Road, Heping District, Tianjin 300020, China ; Department of Ophthalmology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
Biomed Res Int. 2015;2015:207312. doi: 10.1155/2015/207312. Epub 2015 Jan 11.
The aim was to investigate the effects of the GABAB receptor antagonist, CGP46381, on form-deprivation myopia (FDM) in guinea pigs. Twenty-four guinea pigs had monocular visual deprivation induced using a diffuser for 11 days (day 14 to 25). The deprived eyes were treated with daily subconjunctival injections (100 μl) of either 2% CGP46381, 0.2% CGP46381, or saline or received no injection. The fellow eyes were left untreated. Another six animals received no treatment. At the start and end of the treatment period, ocular refractions were measured using retinoscopy and vitreous chamber depth (VCD) and axial length (AL) using A-scan ultrasound. All of the deprived eyes developed relative myopia (treated versus untreated eyes, P < 0.05). The amount of myopia was significantly affected by the drug treatment (one-way ANOVA, P < 0.0001). The highest dose tested, 2% CGP46381, significantly inhibited myopia development compared to saline (2% CGP46381: -1.08 ± 0.40 D, saline: -4.33 ± 0.67 D, P < 0.01). The majority of these effects were due to less AL (2% CGP46381: 0.03 ± 0.01 mm, saline: 0.13 ± 0.02 mm, P < 0.01) and VCD (2% CGP46381: 0.02 ± 0.01 mm, saline: 0.08 ± 0.01 mm, P < 0.01) elongation. The lower dose tested, 0.2% CGP46381, did not significantly inhibit FDM (P > 0.05). Subconjunctival injections of CGP46381 inhibit FDM development in guinea pigs in a dose-dependent manner.
目的是研究GABAB受体拮抗剂CGP46381对豚鼠形觉剥夺性近视（FDM）的影响。24只豚鼠使用扩散器诱导单眼视觉剥夺11天（第14天至25天）。对剥夺眼每日进行结膜下注射（100μl），注射2% CGP46381、0.2% CGP46381或生理盐水，或不进行注射。对侧眼不进行处理。另外6只动物不进行任何处理。在治疗期开始和结束时，使用视网膜检影法测量眼屈光，使用A超超声测量玻璃体腔深度（VCD）和眼轴长度（AL）。所有剥夺眼均出现了相对近视（治疗眼与未治疗眼相比，P < 0.05）。近视程度受到药物治疗的显著影响（单因素方差分析，P < 0.0001）。所测试的最高剂量2% CGP46381与生理盐水相比，显著抑制了近视的发展（2% CGP46381：-1.08 ± 0.40 D，生理盐水：-4.33 ± 0.67 D，P < 0.01）。这些影响主要是由于AL（2% CGP46381：0.03 ± 0.01 mm，生理盐水：0.13 ± 0.02 mm，P < 0.01）和VCD（2% CGP46381：0.02 ± 0.01 mm，生理盐水：0.08 ± 0.01 mm，P < 0.01）伸长较少。所测试的较低剂量0.2% CGP46381并未显著抑制FDM（P > 0.05）。结膜下注射CGP46381以剂量依赖方式抑制豚鼠FDM的发展。
